Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of neoadjuvant therapy on general anesthesia and recovery in esophageal cancer
ChiCTR2400091433Phase 4Not yet recruiting
- Sponsor
- Cancer Hospital of Shantou University Medical College Department of Anesthesiology
- Start
- Oct 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of propofol and remifentanil in esophageal cancer (2 arms), sponsored by Cancer Hospital of Shantou University Medical College Department of Anesthesiology. Primary endpoints: Effect-site target concentration of propofol at sleep onset, Bispectral index (BIS) of EEG at sleep onset and 2 more. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
propofolremifentanil
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR2400091433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091433.